Last reviewed · How we verify
NCT00001310
Tissue Studies of Human Eye Diseases
trial in Retinal Disease in 3,833 participants. Terminated before completion.
Quick facts
| Lead sponsor | National Eye Institute (NEI) |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 3,833 |
| Start date | 5 March 1992 |
| Estimated completion | 16 September 2015 |
| Sites | 1 location across United States |
Conditions studied
- Retinal Disease — all drugs for Retinal Disease →
- Corneal Disease — all drugs for Corneal Disease →
- Diabetic Retinopathy — all drugs for Diabetic Retinopathy →
- Uveitis — all drugs for Uveitis →
Sponsor
National Eye Institute (NEI)
Who can join
Eligibility, any sex, with Retinal Disease or Corneal Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this project is to diagnose and evaluate ocular and related tissues with various diseases such as conjunctival, corneal, uveal, vitreoretinal and optic nerve disorders, ocular degenerative, metabolic or genetic diseases and tumors. These will be studied using light microscopy, electron microscopy, confocal microscopy, immunohistochemistry, molecular pathological including polymerase chain reaction and in situ hybridization, as well as measuring the functions of cellular organelles, e.g., mitochondrial function. Lymphocytes in the peripheral blood as well as other involved biopsied tissues and ocular tissue will be compared and categorized by disease. Cytokines, chemokines or growth factors and/or other released molecules in the blood and ocular fluids will be also analyzed. Elucidating the relationship between the infiltrating cells, ocular resident cells, and their products in various diseases will help us to make diagnoses and increase our understanding of human ocular disorders. Patients who require eye surgery to treat an eye disease or other disease in which the eye is involved may participate in this study. Samples of eye tissue and fluid that are normally removed and discarded during eye surgery will instead be given to researchers for study. The tissues will be examined under microscope and studied using sophisticated chemical and biological tests. Immune cells from blood samples may also be examined. These studies will help better understand and diagnose the various eye diseases and to develop more attractive therapies.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT00001310
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Retinal Disease
Currently open trials in the same condition.
- NCT07149740 — Data Gathering for A10900 · recruiting
- NCT06852963 — A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Parti · Phase 1, PHASE2 · recruiting
- NCT05699096 — Perfluorooctyl Bromide Which Empowers the Liquid to Flat the Detached Retina and Displace the Underneath Fluids Anterior · recruiting
- NCT06289452 — Safety and Efficacy Study of IVB102 Injection in Subjects With X-linked Retinoschisis · EARLY_PHASE1 · active not recruiting
- NCT06520410 — Safety and Efficacy of 18 mm Short Vitrectomy Probe for Pediatric Vitreoretinal Surgeries · Phase 4 · recruiting
Other National Eye Institute (NEI) trials
Trials by the same sponsor.
- NCT06491615 — National Ophthalmic Genotyping and Phenotyping Network (eyeGENE (Registered Trademark)), Stage 3 - Expansion of DNA and · recruiting
- NCT04289571 — Virtual Reality Mobility Assessment of Functional Vision in Retinal Disease · Phase 1 · recruiting
- NCT04833361 — Potential Environmental Causes of Uveal Coloboma · completed
- NCT06670989 — Training to Modify Fixational Eye Movements for Optimizing Visual Performance in People With Central Vision Loss · NA · active not recruiting
- NCT04591483 — Stargardt-like Macular Dystrophy (STDG3) Secondary to Mutations in ELOVL4 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00001310 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Eye Institute (NEI)
- Last refreshed: 9 December 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00001310.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing